NovoCure (NVCR) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.28%. A quarter ago, it was expected that this oncology drug developer would post a loss of $0.53 per share when it actually produced a loss of $0.45, delivering a surprise of 15.09%.Over the last four quarters, the company has ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q (Exact Name of Registrant as Specified in Its Charter) For the quarterly period ended March 31, 2024 (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organization) Identification No.) or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Jersey 98-1057807 For the transition period from to Commission File Number 001- ...

Exhibit 99.1 Novocure Reports First Quarter 2024 Financial Results Quarterly net revenues of $139 million, up 13% year-over-year, with 3,845 active patients on therapy as of March 31, 2024 Phase 3 METIS trial in brain metastases from non-small cell lung cancer met primary endpoint and will be presented as late-breaking abstract at ASCO 2024 LUNAR PMA application for TTFields in NSCLC Day 100 FDA meeting complete Root, Switzerland – Novocure (NASDAQ: NVCR) today reported financial results for the quarter end ...

NovoCure Limited (NASDAQ:NVCR) Q4 2023 Earnings Conference Call February 22, 2024 8:00 AM ET Company Participants Ingrid Goldberg - Investor Relations Bill Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Ashley Cordova - Chief Financial Officer Frank Leonard - Executive VP and President of NovoCure Oncology Pritesh Shah - Chief Growth Officer Conference Call Participants Jason Bednar - Piper Sandler Jonathan Chang - Leerink Partners Emily Bodnar - H.C. Wainwright Operator Good day and tha ...

q4 2023 selected financial highlights patientforward® @ 2024 Novocure GmbH 9 novocure® Optune Lua® and Optune Gio® indications for use and important safety information novocure® | --- | --- | --- | --- | |----------------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | Novocure | | | | | Q4 2023 Earnings Thursday, February 22, 2024 | | | | forward-looking statements ln addition to historical facts or statements of current condition, this presentation may contain forwar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________________ FORM 10-K ______________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Nu ...

patientforward HR, hazard ratio; ICI, immune checkpoint inhibitor; TTFields, Turnor Treating Fields; © 2023 Novocure GmbH phase 3 LUNAR trial met primary overall survival endpoint Overall survival (ITT population) 1.0 1.0 · 0.9 0.9 13.2 9.9 18.5 Median OS (months) MedianOS (months) 10.8 0.8 0.8 Log-rank P-value 0.035 0.03 Log-rank P-value HR (95% CI) HR (95% CI) 0.74 (0.56-0.98) 0.63 (0.41-0.96) 0.7 0.7 7% (2-15) 3-year survival (95% Cl) 18% (11-27) 3-year survival (95% Cl) 27% (15-42) 9% (3-21) bability of ...

NovoCure Limited (NASDAQ:NVCR) Q3 2023 Earnings Conference Call October 26, 2023 8:00 AM ET Company Participants Ingrid Goldberg - Investor Relations Bill Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Ashley Cordova - Chief Financial Officer Pritesh Shah - Chief Growth Officer Uri Weinberg - Chief Innovation Officer Conference Call Participants Jonathan Chang - Leerink Partners Lei Huang - Wells Fargo Emily Bodnar - H.C. Wainwright Operator Welcome to the NovoCure Q3 2023 Earnings Confe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37565 NovoCure Limited Washington, D.C. 20549 _______________________________________________________ (Exact Name of Registrant as Specified in Its ...

For the quarterly period ended June 30, 2023 Washington, D.C. 20549 _______________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37565 NovoCure Limited (Exact Name of Registrant as Specified in Its Char ...